Zobrazeno 1 - 10
of 84
pro vyhledávání: '"Gary J Noel"'
Autor:
Lisa V Adams, Sienna R Craig, Elia John Mmbaga, Helga Naburi, Timothy Lahey, Cameron T Nutt, Rodrick Kisenge, Gary J Noel, Stephen P Spielberg
Publikováno v:
PLoS ONE, Vol 8, Iss 3, p e58303 (2013)
OBJECTIVE: The dearth of age-appropriate formulations of many medicines for children poses a major challenge to pediatric therapeutic practice, adherence, and health care delivery worldwide. We provide information on current administration practices
Externí odkaz:
https://doaj.org/article/32abdfff212f41df93e14a004978de80
Publikováno v:
Pediatric Research
Autor:
Edward M. Connor, Robert M. Nelson, Christina Bucci-Rechtweg, Dionna J Green, Ronald J. Portman, Thomas Miller, Gary J. Noel, Carmen Moreno, Donna L. Snyder, Collin Hovinga
Publikováno v:
Therapeutic Innovation & Regulatory Science
Including adolescents in adult clinical trials can play an important role in making innovative new medicines available to children in a timelier fashion. Stakeholders involved in the processes leading to regulatory approval and labeling of new drugs
Publikováno v:
Pediatric Research
Autor:
Gary J, Noel, Edward, Connor
Publikováno v:
The Pediatric infectious disease journal. 39(9)
Publikováno v:
Journal of the Pediatric Infectious Diseases Society
The Clinical Trials Transformation Initiative convened with several groups in the pediatric antibacterial drug development community with the goal of identifying challenges and recommending ways to improve current practice. Attention to 5 major areas
Autor:
Chris Wheeler, Amy Corneli, Gary J. Noel, Jamie N. Roberts, Daniel K. Benjamin, John S. Bradley, Sumathi Nambiar, Li Lin, Breck Gamel
Publikováno v:
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications, Vol 9, Iss C, Pp 115-120 (2018)
Contemporary Clinical Trials Communications, Vol 9, Iss C, Pp 115-120 (2018)
An urgent need exists to develop new antibacterial drugs for children. We conducted research with investigators of pediatric antibacterial drug trials to identify facilitators and barriers in the conduct of these trials. Seventy-three investigators c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0664dedb29868cd5ef187a4956cf8f5c
https://escholarship.org/uc/item/92n0p25v
https://escholarship.org/uc/item/92n0p25v
Autor:
Amy Corneli, Li Lin, Daniel K. Benjamin, Sumathi Nambiar, Hasan S. Jafri, P. Brian Smith, Chris Wheeler, John Farley, Gary J. Noel, John S. Bradley, Rosemary Tiernan, Jamie N. Roberts, Rachel G. Greenberg
Publikováno v:
Contemporary Clinical Trials Communications, Vol 9, Iss C, Pp 7-12 (2018)
Contemporary Clinical Trials Communications
Contemporary Clinical Trials Communications
Despite legislation to stimulate pediatric drug development through clinical trials, enrolling children in trials continues to be challenging. Non-investigator (those who have never served as a clinical trial investigator) providers are essential to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5479429b229114e92ab00a476893ade3
https://escholarship.org/uc/item/84j1k4n1
https://escholarship.org/uc/item/84j1k4n1
Publikováno v:
Antimicrobial Agents and Chemotherapy. 56:5650-5654
A randomized, investigator-blind, multicenter phase 2 trial involving patients with complicated skin and skin structure infections (cSSSI) compared the safety and efficacy of omadacycline, a broad-spectrum agent with activity against methicillin-resi
Autor:
Demissie Alemayehu, Gary J. Noel, Pamela Tenearts, Christina Reith, Rosemary Tiernan, Charles Knirsch, Sabrina Comic-Savic, Eric Pelfrene, Jonas Santiago, Vance G. Fowler, Jennifer C. Goldsack, Kunal Merchant, David Friedland, Radu Botgros, Thomas L. Holland
Publikováno v:
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 63
Background The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections. The evaluation of new antibacterial drugs for efficacy in this population is important, as many antibacteri